These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 8470880

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Cell surface antigens of human bladder tumors: definition of tumor subsets by monoclonal antibodies and correlation with growth characteristics.
    Fradet Y, Cordon-Cardo C, Whitmore WF, Melamed MR, Old LJ.
    Cancer Res; 1986 Oct; 46(10):5183-8. PubMed ID: 3756873
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Expression of cell cycle proteins in T1a and T1b urothelial bladder carcinoma and their value in predicting tumor progression.
    Mhawech P, Greloz V, Oppikofer C, Szalay-Quinodoz I, Herrmann F.
    Cancer; 2004 Jun 01; 100(11):2367-75. PubMed ID: 15160340
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. p53 expression compared with other prognostic factors in OMS grade-I stage-Ta transitional cell carcinoma of the bladder.
    Casetta G, Gontero P, Russo R, Pacchioni D, Tizzani A.
    Eur Urol; 1997 Jun 01; 32(2):229-36. PubMed ID: 9286659
    [Abstract] [Full Text] [Related]

  • 10. [Prognostic value of the immunohistochemical expression of: Ki67, p53, PCNA and Bcl2 in the superficial tumors of the bladder].
    Rammeh-Rommani S, Zermani R, Sfaxi M, Chabchoub A, Zouari B, Ayed M, Ben Jilani-Baltagi S.
    Tunis Med; 2007 Jun 01; 85(6):509-12. PubMed ID: 17644907
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Contribution of monoclonal antibodies within the framework of urothelial tumors of the bladder].
    Chopin DK.
    Pathol Biol (Paris); 1988 Apr 01; 36(4):301-8. PubMed ID: 3287299
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value.
    Spyratos F, Ferrero-Poüs M, Trassard M, Hacène K, Phillips E, Tubiana-Hulin M, Le Doussal V.
    Cancer; 2002 Apr 15; 94(8):2151-9. PubMed ID: 12001111
    [Abstract] [Full Text] [Related]

  • 18. Characterization of the DD23 tumor-associated antigen for bladder cancer detection and recurrence monitoring. Marker Network for Bladder Cancer.
    Bonner RB, Liebert M, Hurst RE, Grossman HB, Bane BL, Hemstreet GP.
    Cancer Epidemiol Biomarkers Prev; 1996 Dec 15; 5(12):971-8. PubMed ID: 8959319
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Evaluations of protein p53 overexpression in cancer of the bladder: prognostic value].
    Popov Z, Hoznek A, Colombel M, Bastuji S, Abbou CC, Chopin DK.
    Chirurgie; 1996 Dec 15; 121(6):461-9. PubMed ID: 8978142
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.